Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Valiltramiprosate - Alzheon

X
Drug Profile

Valiltramiprosate - Alzheon

Alternative Names: ALZ 801; BLU-8499; NRM-8499; Tramiprosate prodrug - Alzheon

Latest Information Update: 08 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BELLUS Health
  • Developer Alzheon; BELLUS Health; National Institute on Aging
  • Class Alkanesulfonic acids; Antidementias; Neuroprotectants; Propylamines; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease
  • Phase II Cerebral amyloid angiopathy; Down syndrome

Most Recent Events

  • 30 Apr 2024 Alzheon initiates enrolment in the APOLLOE4-LTE phase III long-term extension trial for Alzheimer's disease (Early-stage disease) in USA, Canada and United Kingdom (PO, Tablet) (NCT06304883)
  • 30 Apr 2024 Alzheon plans a phase III trial for Alzheimer's disease (PO, Tablet)
  • 13 Apr 2024 Updated efficacy data from a phase II trial in Alzheimer's disease presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top